Yanqiu Zhao

Phase II Dose-Randomized Study of Sunvozertinib in Platinum-Pretreated Non–Small Cell Lung Cancer With Epidermal Growth Factor Receptor Exon 20 Insertion Mutations (WU-KONG1B)

Genetic biomarker study of sunvozertinib for clinical prognosis and prediction in NSCLC with EGFR exon 20 insertion mutation

Combination of pre-transplant flow cytometry, WT1 expression, and NGS for MRD monitoring is potent in predicting the prognosis of AML receiving allogeneic transplantation

Sosimerasib monotherapy in patients with previously treated KRAS G12C–mutated non-small cell lung cancer: Primary results of a phase 2 study.

Extramedullary relapse of acute lymphoblastic leukemia treated with a CAR-T cell therapy bridge to unrelated cord blood transplantation: a case report and review of the literature

Profound dFLC decrease after one cycle predicts superior outcome in patients with AL amyloidosis

Plasma ctDNA biomarker study in patients with non-small cell lung cancer with EGFR exon 20 insertion mutation treated with sunvozertinib.

Amivantamab plus chemotherapy vs chemotherapy as first-line treatment among patients with EGFR exon 20 insertion–mutated advanced non-small cell lung cancer (NSCLC): PAPILLON Chinese subgroup analysis.

Efficacy and safety of an HDACi- and HMA-based protocol in adults with acute myeloid leukemia of intermediate- and adverse-risk categories: a retrospective study

miR-603 promotes cell proliferation and differentiation by targeting TrkB in acute promyelocytic leukemia

Single-Center Retrospective Clinical Evaluation of Venetoclax Combined with HMAs and Half-Dose CAG for Unfit or Refractory/Relapsed AML

Knockdown of ADORA2A antisense RNA 1 inhibits cell proliferation and enhances imatinib sensitivity in chronic myeloid leukemia

Targeting FHL1 impairs cell proliferation and differentiation of acute myeloid leukemia cells

Knockdown of ADORA2A antisense RNA 1 inhibits cell proliferation and enhances imatinib sensitivity in chronic myeloid leukemia

Adding 5-day decitabine to the conditioning regimen for haploidentical bone marrow transplantation in aplastic anaemia patients results in satisfactory clinical outcomes

Gene mutations in acute promyelocytic leukemia early death in patients treated with arsenic trioxide alone

Effectiveness of platelet rich plasma in burn wound healing: a systematic review and meta-analysis

Growth inhibition and suppression of the mTOR and Wnt/β‐catenin pathways in T‐acute lymphoblastic leukemia by rapamycin and <i>MYCN</i> depletion

&lt;p&gt;Assessment of the presence and anti-tumor potential of tumor-infiltrating lymphocytes in patients with acute myeloid leukemia&lt;/p&gt;

<i><scp>MYCN</scp></i> is a novel oncogenic target in adult B‐<scp>ALL</scp> that activates the Wnt/β‐catenin pathway by suppressing <i><scp>DKK</scp>3</i>

Development of a risk grading system to identify patients with acute promyelocytic leukemia at high risk of early death

A novel TAL1/miR-149* axis accelerates tumor growth of human T cell acute lymphoblastic leukemia.

Suppression of miR-708 inhibits the Wnt/β-catenin signaling pathway by activating DKK3 in adult B-all

Difference in causes and prognostic factors of early death between cohorts with de novo and relapsed acute promyelocytic leukemia

Time-series analysis in imatinib-resistant chronic myeloid leukemia K562-cells under different drug treatments

Suppression of Mir-708 Promotes DKK3 to Inhibit Wnt/β-Catenin Signaling Pathway in Adult B-ALL

miRNA-149* promotes cell proliferation and suppresses apoptosis by mediating JunB in T-cell acute lymphoblastic leukemia

Identification of potential therapeutic target genes, key miRNAs and mechanisms in acute myeloid leukemia based on bioinformatics analysis

The relationship between Th1/Th2 cytokine and glucocorticoidresistant idiopathic thrombocytopenia purpura